Abstract
Serum biomarkers are molecules produced by normal and abnormal cells. Prostate specific antigen (PSA) is an example of a serum biomarker used widely in the diagnosis and prognostication of prostate cancer. PSA has its limitations as it is organ- but not cancer-specific. The aim of this review is to summarize the current published data on the potential prognostic and predictive biomarkers in metastatic prostate cancer (mPC) that can be used in conjunction with PSA. These biomarkers include microRNAs, androgen receptor variants, bone metabolism, neuroendocrine and metabolite biomarkers, and could guide treatment selection and sequence in an era where we strive to personalized therapy.
Highlights
Prostate cancer is the second most commonly diagnosed cancer in males worldwide and the fifth most frequent cause of cancer related death in men worldwide
The aim of this review is to summarise the current published data focussing on a selection of promising biomarkers with the potential to improve the prognostic and predictive accuracy of Prostate specific antigen (PSA)
The aim of this review is to summarise the current published data focussing on a selection of promising biomarkers with the potential to improve the prognostic and predictive accuracy of PSA 2 of 10 in metastatic prostate cancer (mPC)
Summary
Prostate cancer is the second most commonly diagnosed cancer in males worldwide and the fifth most frequent cause of cancer related death in men worldwide It is a heterogenous condition ranging from relatively indolent to aggressive disease. Circulating serum biomarkers are molecules produced by normal and abnormal cells. Prostate specific antigen (PSA) is an example of a serum biomarker used widely in the diagnosis and prognostication of prostate cancer and in assessing response to treatment. It is a kallikrein protease produced by the luminal cells in the prostate gland. Novel biomarkers are needed in prostate cancer to improve the prognostic and predictive accuracy of PSA, imaging and biopsy alone [9,10]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
